Newer dual agonists, such as tirzepatide (which targets both GLP-1 and GIP receptors), may have different tolerability profiles, though they can also cause similar gastrointestinal effects
[PubMed] [Google Scholar] 15.Lu S.C
Payout amounts will depend on the specific injury and the quality of life after sustaining the injury
Up to 30% of overall trial population could have T2D, but no stratification by T2D status was conducted at randomization.2 Patients in either arm can be on standard of care (e.g., anti-amyloid antibody or memantine)
7.4 Clinical interpretation of divergent response phenotypes From a clinical perspective, patient-reported eating-experience changes during GLP-1RA therapy should be interpreted in relation to the dominant response phenotype rather than assumed to reflect a uniform treatment effect
Curr Opin Opththamol 2013;24:239-245